Imfinzi (durvalumab) is a type of immunotherapy used to treat types of lung cancer (NSCLC, SCLC), biliary tract cancer (BTC), hepatocellular carcinoma, and endometrial cancer. Includes Imfinzi side effects, interactions, indications. and package insert.
IMFINZI (durvalumab) Prior Auth Criteria Proprietary Information. Restricted Access Do not disseminate or copy without approval. 2024, Magellan Rx Management VII. References 1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; August 2024. Accessed February 2024. 2.
(Imfinzi 2024). Durvalumab is a human IgG1 Tecentriq (atezolizumab) [package insert] (2024) Genetech, Inc, South San Francisco.
Imfinzi 120 mg/2.4 mL single-dose vial: xx Imfinzi 500 mg/10 mL single-dose vial: xx VII. References 1. Imfinzi [package insert]. Wilmington, DE; AstraZeneca Pharmaceuticals LP; November 2024. Accessed November 2024.
Imfinzi (durvalumab) is a type of immunotherapy used to treat types of lung cancer (NSCLC, SCLC), biliary tract cancer (BTC), hepatocellular carcinoma, and endometrial cancer. Includes Imfinzi side effects, interactions, indications. and package insert.
Imfinzi package insert / prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions and pharmacology.
by JC Liu 2024 Cited by 3tremelimumab (AstraZeneca).9,10 These two inhibi- tors IMFINZI (durvalumab) [package insert]. Wilmington, DE: AstraZeneca
Imfinzi (durvalumab) is a type of immunotherapy used to treat types of lung cancer (NSCLC, SCLC), biliary tract cancer (BTC), hepatocellular carcinoma, and endometrial cancer. Includes Imfinzi side effects, interactions, indications. and package insert.
(U.S. Food and Drug Administration 2024). Policy Imfinzi (durvalumab) is Imfinzi [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP
I would like to know more about this package. ^.^